Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted marketing authorization ...

Gilead Sciences won European approval Tuesday for its new twice-annual HIV prevention shot, now called Yeytuo.

The European Commission has granted marketing authorization for Gilead Sciences' twice-yearly injection for preventing HIV infection, the company said on Tuesday.

In this article, we will take a detailed look at the Top 10 Trending Stocks to Watch Ahead of Nvidia Earnings.

While Gilead Sciences posted a strong Q2 earnings print, GILD stock saw profit-taking. Here's why the red ink could be an ...

Kite, the Santa Monica, California-based cell therapy subsidiary of Gilead, has entered a definitive agreement to pay $350 ...

Interius is working on a more efficient way to deliver CAR-T therapy to patients. Unlock Digital Access for unlimited access to Inquirer.com and The Inquirer App, plus 5 articles per month to gift to ...

Kite Pharma is acquiring Interius BioTherapeutics for $350 million, adding in vivo CAR T technology that could simplify treatment and expand patient access.

The biotech published an earnings report that fell short of expectations. It whiffed on both the top and bottom lines. Roivant reported that its revenue for the period was slightly under $2.2 ...

$100+ Billion Infectious Disease Treatment Markets, 2030 with Gilead Sciences, GSK, Sanofi, Merck, and Abbott Dominating - ResearchAndMarkets.com ...

Gilead Sciences Inc. (NASDAQ: GILD) is one of the most undervalued quality stocks to buy according to hedge funds. On July 25, the European Medicines Agency’s Committee for Medicinal Products ...

Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong HIV ...